Abstract
Objective: 1) To find out whether the symptoms attributable to adenoid hypertrophy in adolescents may be treated with intranasal mometasone furoate (MF) application. 2) To learn if adenoid hypertrophy in adolescents may decrease in size with intranasal MF.
Method: A prospective, double-blind, randomized, crossover study was conducted in 28 subjects (12-18 years) with adenoidal hypertrophy. Subjects used intranasal MF or placebo for a duration of 6 weeks with a washout period of 3 weeks. Subjective symptoms and adenoid size were evaluated.
Results: At the initiation of the study, there was no significant difference between the mean symptom scores for any of the sinonasal symptoms between the 2 treatment groups. Placebo users had no statistically significant reduction in their sinonasal symptoms (P > .05 for all) other than snoring (P = .011). MF users had a statistically significant reduction in all symptoms (P < .05 for all) other than coughing (P = .527). There was a significant difference between the 2 treatment groups in the mean posttreatment scores for total subjective symptom scoring and rhinorrhea (P = .031, P = .012 resp). There was no significant difference in baseline endoscopy scores between the 2 treatment groups (P = .317). There was a significant reduction in nasal endoscopy scores in the MF group compared to placebo group (P = .034).
Conclusion: MF may have some advantage over placebo for the symptoms attributable to adenoid hypertrophy in adolescents. Intranasal MF decreases the size of the adenoid hypertrophy in this group of patients.
Get full access to this article
View all access options for this article.